Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
ChiCTR2100055096Phase 4Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing sintilimab + cCRT with Control: placebo + cCRT (2 arms). Primary endpoint: Progression-free survival. Started Feb 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100055096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100055096.